Article Dans Une Revue Blood Année : 2022

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Matthew Koster
  • Fonction : co premier-auteur
Joris Galland
Guillaume Le Guenno
Yvan Jamilloux

Résumé

VEXAS syndrome (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X-linked, autoinflammatory manifestations and somatic) is an autoinflammatory condition caused by somatically acquired UBA1 mutations. Heiblig et al report on an international retrospective analysis of 30 patients with VEXAS syndrome treated with different Janus kinase (JAK) inhibitors, finding encouraging evidence supporting the use of the JAK1/2 inhibitor ruxolitinib with clinical remissions and reductions in steroid use seen in the majority of patients.

Dates et versions

hal-04907677 , version 1 (23-01-2025)

Identifiants

Citer

Maël Heiblig, Marcela Ferrada, Matthew Koster, Thomas Barba, Mathieu Gerfaud-Valentin, et al.. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood, 2022, 140 (8), pp.927-931. ⟨10.1182/blood.2022016642⟩. ⟨hal-04907677⟩
89 Consultations
0 Téléchargements

Altmetric

Partager

  • More